http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20080121-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2007-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5078f0ccc603e21b5c62b9ba6b42771
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c82db8dfc1f399a3496f579bbb3197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c07c2cf87a6f27b3aaec04cb051a11f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6385f2ff53f1209c82fd3ecb5b858c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32be5e9c3039eaf941c987c11247ed98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa02643a3da5e86ec50f37cefe5eb92e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fc91955b10b5799041ce418f59f2bb2
publicationDate 2008-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PE-20080121-A1
titleOfInvention METHODS TO REDUCE PROTEIN AGGLOMERATION
abstract IT REFERS TO A FORMULATION THAT CONTAINS: A) A PROTEIN SELECTED FROM ANTIBODY SUCH AS ANTIB7.1, ANTIB7.2, ANTI CD22, COAGULATION FACTOR, ENZYME, TRANSCRIPTION FACTOR, AMONG OTHERS IN A CONCENTRATION OF 0.1 mg / ml AND 300 mg / ml; B) SURFACTANT SELECTED FROM POLYSORBATE-20 OR POLYSORBATE-80; C) AMINO ACID SELECTED FROM ARGININE, LYSINE, GLYCINE, GLUTAMIC ACID, AMONG OTHERS; C) TONICITY MODIFIER SELECTED AMONG SODIUM CHLORIDE, MANNITOL, SORBITOL. ADDITIONALLY IT INCLUDES A SELECTED SUGAR OF SACROSE, TREHALOSE AND MANNITOL. METHIONINE IS ADDED TO SUCH FORMULATION AT A CONCENTRATION OF 0.5mM AND 145mM IN ORDER TO GET A REDUCED AGGLOMERATION OF PROTEIN IN THE FORMULATION COMPARED TO PROTEIN IN A FORMULATION THAT LACKS METHIONINE
priorityDate 2006-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526338
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID554810
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82170
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426484532
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585166
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID12483
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6137
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415853316
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID933
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7427
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10925912
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534805
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490943
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487901
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537510
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5780

Total number of triples: 51.